Table 1.

Demographic and clinical variables for NMIBC patients of the TXBCS

NMIBC (n = 419)
Recurrence, n (%)Progression, n (%)
Yes (n = 228)No (n = 191)P*Yes (n = 71)No (n = 347)P*
Sex0.030.05
    Male195 (56.8)148 (43.2)64 (18.7)278 (81.3)
    Female33 (43.4)43 (56.6)7 (9.2)69 (90.8)
Age (y)
    Mean (SD) y63.0 (11.2)63.6 (11.4)0.6366.2 (9.9)62.7 (11.5)0.02
Smoking status0.630.40
    Never64 (52.5)58 (47.5)16 (13.2)105 (86.8)
    Former117 (56.8)89 (43.2)37 (18.0)169 (82.0)
    Current47 (51.6)44 (48.4)18 (19.8)73 (80.2)
Stage0.28<0.01
    Ta105 (54.4)88 (45.6)21 (10.9)172 (89.1)
    Tis16 (69.6)7 (30.4)7 (30.4)16 (69.6)
    T1104 (52.0)96 (48.0)42 (21.1)157 (78.9)
Grade (G)0.20<0.01
    G15 (31.2)11 (68.8)1 (6.2)15 (93.8)
    G281 (54.0)69 (46.0)12 (8.0)138 (92.0)
    G3128 (54.0)109 (46.0)53 (22.5)183 (77.5)
Treatment<0.01<0.01
    TUR97 (66.4)49 (33.6)16 (11.0)129 (89.0)
    iBCG91 (74.6)31 (25.4)37 (30.3)85 (69.7)
    mBCG30 (36.6)52 (63.4)15 (18.3)67 (81.7)
    Others10 (16.7)50 (83.3)3 (5.0)57 (95.0)

NOTE: The numbers of each variable may not add up to 419 due to missing data.

  • *P values were derived from Pearson's χ2 test or Fisher's exact test for categorical variables, and Student's t test for continuous variables.

  • Smoking status: individuals who had smoked more than 100 cigarettes in their lifetime were defined as ever smokers; others were never smokers. Smokers included current smokers and former smokers. Individuals who had quit smoking at least 1 y before diagnosis were categorized as former smokers.

  • Treatment: TUR, subgroup who had no further therapy after TUR; iBCG, subgroup who received iBCG after TUR; mBCG, subgroup who further received mBCG after the TUR and iBCG treatment; and others, which included those who received intravesical chemotherapy but no BCG.